Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 129034, 6 pages
http://dx.doi.org/10.1155/2015/129034
Review Article

Cytokines as Mediators of Pain-Related Process in Breast Cancer

1Laboratory of Inflammatory Mediators, State University of West Paraná, UNIOESTE, Campus Francisco Beltrão, Rua Maringá 1200, 85605-010 Francisco Beltrão, PR, Brazil
2Laboratory of Immunoparasitology, State University of Londrina, UEL, PR, Brazil

Received 23 May 2015; Revised 16 October 2015; Accepted 25 October 2015

Academic Editor: Xue-Jun Song

Copyright © 2015 Carolina Panis and Wander Rogério Pavanelli. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Satija, S. M. Ahmed, R. Gupta et al., “Breast cancer pain management—a review of current & novel therapies,” Indian Journal of Medical Research, vol. 139, no. 2, pp. 216–225, 2014. View at Google Scholar · View at Scopus
  2. A. N. Lozano-Ondoua, A. M. Symons-Liguori, and T. W. Vanderah, “Cancer-induced bone pain: mechanisms and models,” Neuroscience Letters A, vol. 557, pp. 52–59, 2013. View at Publisher · View at Google Scholar
  3. C. Panis, V. J. Victorino, A. C. S. A. Herrera et al., “Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer,” Breast Cancer Research and Treatment, vol. 133, no. 3, pp. 881–888, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Prat, J. S. Parker, C. Fan, and C. M. Perou, “PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer,” Breast Cancer Research and Treatment, vol. 135, no. 1, pp. 301–306, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Harbeck, C. Thomssen, and M. Gnant, “St. Gallen 2013: brief preliminary summary of the consensus discussion,” Breast Care, vol. 8, no. 2, pp. 102–109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. A. C. S. A. Herrera, C. Panis, V. J. Victorino et al., “Molecular subtype is determinant on inflammatory status and immunological profile from invasive breast cancer patients,” Cancer Immunology, Immunotherapy, vol. 61, no. 11, pp. 2193–2201, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Panis, A. C. S. A. Herrera, V. J. Victorino et al., “Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy,” Breast Cancer Research and Treatment, vol. 133, no. 1, pp. 89–97, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. S. H. Ferreira, “The role of interleukins and nitric oxide in the mediation of inflammatory pain and its control by peripheral analgesics,” Drugs, vol. 46, supplement 1, pp. 1–9, 1993. View at Google Scholar · View at Scopus
  9. W. A. Verri Jr., T. M. Cunha, C. A. Parada, S. Poole, F. Q. Cunha, and S. H. Ferreira, “Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development?” Pharmacology & Therapeutics, vol. 112, no. 1, pp. 116–138, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Chiechi, D. L. Waning, K. R. Stayrook, J. T. Buijs, T. A. Guise, and K. S. Mohammad, “Role of TGF-β in breast cancer bone metastases,” Advances in Bioscience and Biotechnology, vol. 4, no. 10, pp. 15–30, 2013. View at Publisher · View at Google Scholar
  11. M. J. O. Oursler, “Osteoclast synthesis and secretion and activation of latent transforming growth factor β,” Journal of Bone and Mineral Research, vol. 9, no. 4, pp. 443–452, 1994. View at Google Scholar · View at Scopus
  12. E. N. Blaney Davidson, A. P. M. van Caam, E. L. Vitters et al., “TGF-β is a potent inducer of Nerve Growth Factor in articular cartilage via the ALK5-Smad2/3 pathway. Potential role in OA related pain?” Osteoarthritis and Cartilage, vol. 23, no. 3, pp. 478–486, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. J. A. Roman-Blas, D. G. Stokes, and S. A. Jimenez, “Modulation of TGF-β signaling by proinflammatory cytokines in articular chondrocytes,” Osteoarthritis and Cartilage, vol. 15, no. 12, pp. 1367–1377, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Bednarz-Knoll, C. Alix-Panabières, and K. Pantel, “Clinical relevance and biology of circulating tumor cells,” Breast Cancer Research, vol. 13, no. 6, article 228, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. J. T. Buijs, K. R. Stayrook, and T. A. Guise, “TGF-β in the bone microenvironment: role in breast cancer metastases,” Cancer Microenvironment, vol. 4, no. 3, pp. 261–281, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Fazilaty and P. Mehdipour, “Genetics of breast cancer bone metastasis: a sequential multistep pattern,” Clinical & Experimental Metastasis, vol. 31, no. 5, pp. 595–612, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. J. M. Chirgwin and T. A. Guise, “Molecular mechanisms of tumor-bone interactions in osteolytic metastases,” Critical Reviews in Eukaryotic Gene Expression, vol. 10, no. 2, pp. 159–178, 2000. View at Google Scholar · View at Scopus
  18. T. A. Guise, “Molecular mechanisms of osteolytic bone metastases,” Cancer, vol. 88, supplement 12, pp. 2892–2898, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. A. C. Monteiro, A. C. Leal, T. Gonçalves-Silva et al., “T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer,” PLoS ONE, vol. 8, no. 7, Article ID e68171, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Criscitiello, G. Viale, L. Gelao et al., “Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment,” Cancer Treatment Reviews, vol. 41, no. 2, pp. 61–68, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Kaiser, I. Teufel, K. Geiger et al., “Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells,” Breast Cancer Research and Treatment, vol. 140, no. 1, pp. 35–48, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. J. T. Norton, T. Hayashi, B. Crain, M. Corr, and D. A. Carson, “Role of IL-1 receptor-associated kinase-M (IRAK-M) in priming of immune and inflammatory responses by nitrogen bisphosphonates,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 27, pp. 11163–11168, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. B. McCann, C. Miaskowski, T. Koetters et al., “Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery,” The Journal of Pain, vol. 13, no. 5, pp. 425–437, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Stephens, B. A. Cooper, C. West et al., “Associations between cytokine gene variations and severe persistent breast pain in women following breast cancer surgery,” Journal of Pain, vol. 15, no. 2, pp. 169–180, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Ochi-ishi, K. Nagata, T. Inoue, H. Tozaki-Saitoh, M. Tsuda, and K. Inoue, “Involvement of the chemokine CCL3 and the purinoceptor P2X7 in the spinal cord in paclitaxel-induced mechanical allodynia,” Molecular Pain, vol. 10, article 53, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Zhang, J. A. Boyette-Davis, A. K. Kosturakis et al., “Induction of monocyte chemoattractant protein-1 (mcp-1) and its receptor ccr2 in primary sensory neurons contributes to paclitaxel-induced peripheral neuropathy,” Journal of Pain, vol. 14, no. 10, pp. 1031–1044, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. Z.-Z. Huang, D. Li, C.-C. Liu et al., “CX3CL1-mediated macrophage activation contributed to paclitaxel-induced DRG neuronal apoptosis and painful peripheral neuropathy,” Brain, Behavior, and Immunity, vol. 40, pp. 155–165, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Pusztai, T. R. Mendoza, J. M. Reuben et al., “Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy,” Cytokine, vol. 25, no. 3, pp. 94–102, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Fountzilas, D. Skarlos, C. Katsohis et al., “High-dose epirubicin and r-met-hu G-CSF (filgrastim) in the treatment of patients with advanced breast cancer: a hellenic cooperative oncology group study,” Medical and Pediatric Oncology, vol. 24, no. 1, pp. 23–28, 1995. View at Publisher · View at Google Scholar · View at Scopus
  30. K. G. Andersen and H. Kehlet, “Persistent pain after breast cancer treatment: a critical review of risk factors and strategies for prevention,” Journal of Pain, vol. 12, no. 7, pp. 725–746, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Bessler, Y. Shavit, E. Mayburd, G. Smirnov, and B. Beilin, “Postoperative pain, morphine consumption, and genetic polymorphism of IL-1β and IL-1 receptor antagonist,” Neuroscience Letters, vol. 404, no. 1-2, pp. 154–158, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Torres, L. Macdonald, S. D. Croll et al., “Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 10, pp. 1602–1608, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. M. L. Vale, J. B. Marques, C. A. Moreira et al., “Antinociceptive effects of interleukin-4, -10, and -13 on the writhing response in mice and zymosan-induced knee joint incapacitation in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 304, no. 1, pp. 102–108, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. W. A. Macrae, “Chronic post-surgical pain: 10 Years on,” British Journal of Anaesthesia, vol. 101, no. 1, pp. 77–86, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. X.-M. Wang, T. J. Lehky, J. M. Brell, and S. G. Dorsey, “Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy,” Cytokine, vol. 59, no. 1, pp. 3–9, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Mielke, A. Sparreboom, and K. Mross, “Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes,” European Journal of Cancer, vol. 42, no. 1, pp. 24–30, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. A. D. Seidman, R. Portenoy, T.-J. Yao et al., “Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor,” Journal of the National Cancer Institute, vol. 87, no. 17, pp. 1316–1322, 1995. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Ingham, A. Seldman, T.-J. Yao, J. Lepore, and R. Portenoy, “An exploratory study of frequent pain measurement in a cancer clinical trial,” Quality of Life Research, vol. 5, no. 5, pp. 503–507, 1996. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Amadori, G. L. Frassineti, W. Zoli et al., “A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer,” Seminars in Oncology, vol. 23, no. 5, supplement 11, pp. 16–22, 1996. View at Google Scholar · View at Scopus
  40. W. Zheng, W. Huang, S. Liu et al., “Interleukin 10 mediated by herpes simplex virus vectors suppresses neuropathic pain induced by human immunodeficiency virus gp120 in rats,” Anesthesia and Analgesia, vol. 119, no. 3, pp. 693–701, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. C. M. Peters, J. M. Jimenez-Andrade, B. M. Jonas et al., “Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells,” Experimental Neurology, vol. 203, no. 1, pp. 42–54, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Li, H. Zhang, H. Zhang, A. K. Kosturakis, A. B. Jawad, and P. M. Dougherty, “Toll-like receptor 4 signaling contributes to paclitaxel-induced peripheral neuropathy,” Journal of Pain, vol. 15, no. 7, pp. 712–725, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Schäfers and L. Sorkin, “Effect of cytokines on neuronal excitability,” Neuroscience Letters, vol. 437, no. 3, pp. 188–193, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. R. B. Fillingim and R. R. Edwards, “The association of hormone replacement therapy with experimental pain responses in postmenopausal women,” Pain, vol. 92, no. 1-2, pp. 229–234, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Macari, L. F. Duffles, C. M. Queiroz-Junior et al., “Oestrogen regulates bone resorption and cytokine production in the maxillae of female mice,” Archives of Oral Biology, vol. 60, no. 2, pp. 333–341, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. S. D. Brincat, M. Borg, G. Camilleri, and J. Calleja-Agius, “The role of cytokines in postmenopausal osteoporosis,” Minerva Ginecol, vol. 66, no. 4, pp. 391–407, 2014. View at Google Scholar
  47. E. L. Poleshuck, J. Katz, C. H. Andrus et al., “Risk factors for chronic pain following breast cancer surgery: a prospective study,” The Journal of Pain, vol. 7, no. 9, pp. 626–634, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Liu, L. Wang, T. Bongartz et al., “Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression,” Breast Cancer Research, vol. 14, no. 2, article R41, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Shah and S. J. Welsh, “The clinical use of granulocyte-colony stimulating factor,” British Journal of Hospital Medicine, vol. 75, no. 2, pp. C29–C32, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Kubista, J. Glaspy, F. A. Holmes et al., “Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer,” Clinical Breast Cancer, vol. 3, no. 6, pp. 391–398, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Leung, J. Florendo, J. Kano et al., “A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer,” Supportive Care in Cancer, vol. 23, no. 6, pp. 1669–1677, 2015. View at Publisher · View at Google Scholar · View at Scopus